Literature DB >> 14534357

A novel potent radical scavenger, 8-(4-fluorophenyl)-2-((2E)-3-phenyl-2-propenoyl)-1,2,3,4-tetrahydropyrazolo[5,1-c] [1,2,4]triazine (FR210575), prevents neuronal cell death in cultured primary neurons and attenuates brain injury after focal ischemia in rats.

Akinori Iwashita1, Takuya Maemoto, Hirohisa Nakada, Ichiro Shima, Nobuya Matsuoka, Hiroshi Hisajima.   

Abstract

Reactive oxygen species (ROS) play a vital role in brain damage after cerebral ischemia-reperfusion injury, and ROS scavengers have been shown to exert neuroprotective effects against ischemic brain injury. We have recently identified 8-(4-fluorophenyl)-2-((2E)-3-phenyl-2-propenoyl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (FR210575) as a novel, powerful free-radical scavenger. In the present study, the neuroprotective efficacy of FR210575 was evaluated in two neuronal death models in vitro as well as rat focal cerebral ischemia models in vivo. In the first model, primary cortical cultures were exposed to a high oxygen atmosphere (50% O2) for 48 h to induce cell death with apoptotic features. Treatment with FR210575 (10-7-10-5 M) significantly inhibited neuronal death. The second model used a growth-factor withdrawal paradigm. Withdrawal of TIP (transferrin, insulin, putrescine and progesterone)-supplemented medium induced apoptotic cell death after 2 days, but treatment with FR210575 exhibited dramatic protection against neuronal death. In two models of cerebral ischemia [photothrombotic occlusion of middle cerebral artery (MCA) for transient model and by permanent MCA occlusion for permanent model], rats received 3-h intravenous infusion (1-10 mg/kg/3 h) of FR210575, with brain damage determined 24 h later. FR210575 (3.2 mg/kg/3 h) significantly reduced the volume of focal damage in the cortex by 36% in the transient model and also reduced the size of ischemic brain damage in the permanent model. These findings indicate that the powerful radical scavenger FR210575 has potent neuroprotective activity and that FR210575 could be an attractive candidate for the treatment of stroke or other neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534357     DOI: 10.1124/jpet.103.056572

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Involvement of molecular chaperones and the transcription factor Nrf2 in neuroprotection mediated by para-substituted-4,5-diaryl-3-thiomethyl-1,2,4-triazines.

Authors:  Fariba Khodagholi; Niloufar Ansari; Mohsen Amini; Solaleh Khoramian Tusi
Journal:  Cell Stress Chaperones       Date:  2012-01-04       Impact factor: 3.667

2.  Pathophysiology, treatment, and animal and cellular models of human ischemic stroke.

Authors:  Trent M Woodruff; John Thundyil; Sung-Chun Tang; Christopher G Sobey; Stephen M Taylor; Thiruma V Arumugam
Journal:  Mol Neurodegener       Date:  2011-01-25       Impact factor: 14.195

3.  Synthesis, molecular structure and characterization of allylic derivatives of 6-amino-3-methyl-1,2,4-triazolo[3,4-f][1,2,4]-triazin-8(7H)-one.

Authors:  Long-Chih Hwang; Shin-Yi Jane; Hsing-Yi Lai; Chun-Hsien Tu; Gene-Hsiang Lee
Journal:  Molecules       Date:  2006-06-22       Impact factor: 4.411

Review 4.  Some new prospects in the understanding of the molecular basis of the pathogenesis of stroke.

Authors:  Sheikh Arshad Saeed; Kaneez Fatima Shad; Taimur Saleem; Faisal Javed; Muhammad Umair Khan
Journal:  Exp Brain Res       Date:  2007-07-31       Impact factor: 1.972

Review 5.  The potential of tetrandrine as a protective agent for ischemic stroke.

Authors:  Yun Chen; Ya-Hui Tsai; Sheng-Hong Tseng
Journal:  Molecules       Date:  2011-09-16       Impact factor: 4.411

6.  The octadecaneuropeptide ODN protects astrocytes against hydrogen peroxide-induced apoptosis via a PKA/MAPK-dependent mechanism.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Seyma Bahdoudi; Salma Douiri; Jérôme Leprince; Helene Castel; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri; Olfa Masmoudi-Kouki
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.